Program
Etoposide
Also written as “etoposide”, “Etoposide (dose level 1)” and “Etoposide (dose level 2)”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Large B-Cell, Diffuse · Lung Neoplasms · Ovarian Neoplasms, led by 20 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 41 open or running | phase 3since Dec 3, 2020 | Mar 12, 2018 | none ahead |
| Hoffmann-La Roche | 40 open or running | phase 3since Jul 19, 2019 | Oct 20, 2008 | none ahead |
| Bristol-Myers Squibb | 20 open or running | phase 2since Jan 7, 2021 | Feb 20, 2019 | none ahead |
| Jiangsu HengRui Medicine | 20 open or running | phase 3since Jun 24, 2019 | Jun 24, 2019 | none ahead |
| Amgen | 10 open or running | phase 2since Nov 6, 2013 | Nov 6, 2013 | none ahead |
| BeOne Medicines | 10 open or running | phase 2since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| BioNTech | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Boehringer Ingelheim | 11 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | Sep 9, 2028phase 3 · NCT07472517 |
| Eli Lilly | 10 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| EpicentRx | 10 open or running | phase 2since Jun 29, 2015 | Jun 29, 2015 | none ahead |
| Gilead Sciences | 10 open or running | phase 1since Nov 17, 2017 | Nov 17, 2017 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 3since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| lederle-laboratories | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Lee's Pharmaceutical | 10 open or running | phase 1since Apr 13, 2020 | Apr 13, 2020 | none ahead |
| Newsoara HYK Biopharmaceutical (Shanghai) | 11 open or running | phase 2since Jul 2, 2025 | Jul 2, 2025 | Dec 2026phase 2 · NCT07136285 |
| Otsuka | 10 open or running | phase 2since Jul 28, 2009 | Jul 28, 2009 | none ahead |
| Pfizer | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Sanofi | 10 open or running | phase 2since Apr 18, 2006 | Apr 18, 2006 | none ahead |
| swami-rama-cancer-hospital-and-research-institute | 10 open or running | phase 3since Sep 10, 2013 | Sep 10, 2013 | none ahead |
| texas-oncology-cancer-center | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
Also a collaborator on its studies: genelux-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Nov 2, 1999.
- Feb 20, 2019Bristol-Myers Squibb's first study: phase 1 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03850067 · 90 enrolled · France, Italy, Spain
- Apr 29, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT03944772 · 247 enrolled · United States, Denmark, Italy and more
- Jun 24, 2019Jiangsu HengRui Medicine's first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04000295 · 280 enrolled · China
- Jul 19, 2019Phase 3 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04028050 · 155 enrolled · Italy
- Apr 13, 2020Lee's Pharmaceutical's first study: phase 1 study in Extensive Stage Small Cell Lung CancerNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04346914 · 20 enrolled · China
- May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
- Nov 4, 2020Phase 2 study in Small Cell Lung CarcinomaHoffmann-La Roche · NCT04622228 · 56 enrolled · China
- Dec 3, 2020Phase 3 study in Small Cell Lung Carcinoma Extensive DiseaseAstraZeneca · NCT04712903 · 101 enrolled · Spain
- Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT04702880 · 135 enrolled · United States, Australia, Belgium and more
- Feb 25, 2021Phase 3 study in Small Cell Lung CarcinomaAstraZeneca · NCT04774380 · 152 enrolled · Bulgaria, Canada, Czechia and more
- May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseHoffmann-La Roche · NCT05364424 · 43 enrolled · United States
- Jun 3, 2024BioNTech's first study: phase 2 study in Small Cell Lung CarcinomaNew to BioNTechBioNTech · NCT06449209 · 110 enrolled · United States, Australia, South Korea and more
- Jul 2, 2025Newsoara HYK Biopharmaceutical (Shanghai)'s first study: phase 2 study in SCLC, Extensive StageNew to Newsoara HYK Biopharmaceutical (Shanghai)Newsoara HYK Biopharmaceutical (Shanghai) · NCT07136285 · 27 planned · China
- Mar 4, 2026Boehringer Ingelheim's first study: phase 3 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07472517 · 670 planned · United States, Argentina, Australia and more
Ahead
- Dec 2026Primary completion: phase 2 study in SCLC, Extensive StageNewsoara HYK Biopharmaceutical (Shanghai) · NCT07136285
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
- Sep 9, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaBoehringer Ingelheim · NCT07472517
TargetBeta
“DNA topoisomerase II inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07472517Small Cell Lung Carcinoma · United States, Argentina, Australia and more | 3 | Recruiting | Boehringer Ingelheim | Sep 9, 2028 | 670 |
| NCT07136285SCLC, Extensive Stage · China | 2 | Recruiting | Newsoara HYK Biopharmaceutical (Shanghai) | Dec 2026 | 27 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | BioNTech | Jun 2027 | 110 |
| NCT05364424Lymphoma, Large B-Cell, Diffuse · United States | 1 | Completed | Hoffmann-La Roche | Oct 15, 2025 | 43 |
| NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more | 3 | Completed | AstraZeneca | Jun 12, 2023 | 152 |
| NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | May 22, 2025 | 135 |
| NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain | 3 | Completed | AstraZeneca | Jun 21, 2023 | 101 |
| NCT04622228Small Cell Lung Carcinoma · China | 2 | Completed | Hoffmann-La Roche | Jun 21, 2022 | 56 |
| NCT04383977Ovarian Neoplasms | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2020 | 54 |
| NCT04346914Extensive Stage Small Cell Lung Cancer · China | 1 | UNKNOWN | Lee's Pharmaceutical | Oct 30, 2022 | 20 |
| NCT04028050Small Cell Lung Carcinoma · Italy | 3 | Completed | Hoffmann-La Roche | Jul 13, 2023 | 155 |
| NCT04000295Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jan 2021 | 280 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | AstraZeneca | May 6, 2025 | 247 |
| NCT03850067Small Cell Lung Carcinoma · France, Italy, Spain | 1 | Completed | Bristol-Myers Squibb | Jul 16, 2024 | 90 |
| NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more | 1 | Completed | AstraZeneca | Dec 31, 2020 | 105 |
| NCT03432598Lung Neoplasms · China | 2 | Completed | BeOne Medicines | Feb 25, 2019 | 54 |
| NCT03349346Lymphoma, Large B-Cell, Diffuse · France, Italy, Poland and more | 1 | Withdrawn | Gilead Sciences | Feb 2021 | 0 |
| NCT02489903Carcinoma, Small Cell · United States | 2 | Completed | EpicentRx | Dec 6, 2021 | 139 |
| NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation | 2 | Completed | Amgen | Aug 2016 | 32 |
| NCT01947062Lung Neoplasms · India | 3 | UNKNOWN | swami-rama-cancer-hospital-and-research-institute | Jun 2014 | 60 |
| NCT01500161Leukemia, Myeloid, Acute · United States | 2 | Terminated | texas-oncology-cancer-center | Nov 2013 | 1 |
| NCT00948090Lymphoma · United States, Canada | 2 | Completed | Otsuka | May 2013 | 207 |
| NCT00776698Non-Squamous Non-Small Cell Lung Cancer · Netherlands, United Kingdom | 1 | Completed | Hoffmann-La Roche | Feb 2010 | 1 |
| NCT00315705Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | Completed | Sanofi | May 2010 | 50 |
| NCT00191139Carcinoma, Non-Small-Cell Lung · United States, Argentina, China and more | 2 | Completed | Eli Lilly | Nov 2008 | 64 |
| NCT00143455Small Cell Lung Carcinoma · Austria, Belgium, Czech Republic and more | 3 | Completed | Pfizer | Dec 2008 | 485 |
| NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 2004 | 760 |
| NCT00002003Lymphoma, Non-Hodgkin · United States | 2 | Completed | lederle-laboratories |
How it is read
Names in the registry
- “Etoposide”, 18 entries
- “etoposide”, 3 entries
- “Etoposide (dose level 1)”, 1 entry
- “Etoposide (dose level 2)”, 1 entry
- “recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 12 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lung Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.